1027253-87-7Relevant academic research and scientific papers
Discovery of 2-(α-methylbenzylamino) pyrazines as potent Type II inhibitors of FMS
Burns, Christopher J.,Harte, Michael F.,Bu, Xianyong,Fantino, Emmanuelle,Giarrusso, Marilena,Joffe, Max,Kurek, Margarita,Legge, Fiona S.,Razzino, Pasquale,Su, Stephen,Treutlein, Herbert,Wan, Soo San,Zeng, Jun,Wilks, Andrew F.
scheme or table, p. 1206 - 1209 (2009/08/07)
A series of 2-(α-methylbenzylamino) pyrazines have shown to be potent inhibitors of the FMS tyrosine receptor kinase. Details of SAR studies, modeling and synthesis of compounds within this series are reported.
INHIBITORS OF KINASE ACTIVITY
-
Page/Page column 38-39, (2008/12/05)
The present invention relates to pyridines or pyrazines that inhibit kinases. In particular the compounds of the invention inhibit members of the class III PTK receptor family such as FMS (CSF-IR), c-KIT, PDGFRβ, PDGFRα or FLT3 and KDR, SRC, EphA2, EphA3, EphA8, FLTl, FLT4, HCK, LCK, PTK5 (FRK), SYK, DDRl and DDR2 and RET. The compounds of the invention are useful in the treatment of kinase associated diseases such as immunological and inflammatory diseases; hyperproliferative diseases including cancer and diseases involving neo-angiogenesis; renal and kidney diseases; bone remodeling diseases; metabolic diseases; and vascular diseases.
